Pharmaceutical formulations of salmeterol
0 Assignments
0 Petitions
Accused Products
Abstract
There is provided according to the invention a pharmaceutical aerosol formulation which comprises: (i) salmeterol or a pharmaceutically acceptable salt thereof and (ii) a hydrofluoroalkane (HFA) propellant, characterised in that the salmeterol or pharmaceutically acceptable salt thereof is completely dissolved in the formulation.
-
Citations
70 Claims
-
1-27. -27. (Canceled).
-
28. A pharmaceutical aerosol formulation which comprises:
-
(i) salmeterol or a pharmaceutically acceptable salt thereof and (ii) a hydrofluoroalkane (HFA) propellant, wherein the salmeterol or pharmaceutically acceptable salt thereof is dissolved in the formulation, and wherein the formulation is a solution formulation. - View Dependent Claims (29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)
-
-
51. A pharmaceutical aerosol formulation which comprises:
-
(i) 0.025-0.05% w/v salmeterol base;
(ii) 1,1,1,2-tetrafluoroethane as propellant;
(iii) 0.5-3% w/w of a low volatility propellant selected from glycerol and polyethylene glycol; and
(iv) 3-12% w/w ethanol as solubilising agent. - View Dependent Claims (52, 53, 54, 55, 56, 57, 58, 59, 60)
-
-
61. A pharmaceutical aerosol formulation which comprises:
-
(i) 0.025-0.05% w/v salmeterol base;
(ii) 1,1,1,2,3,3,3-heptafluoro-n-propane as propellant;
(iii) 0.5-3% w/w of a low volatility propellant selected from glycerol and polyethylene glycol; and
(iv) 3-12% w/w ethanol as solubilising agent. - View Dependent Claims (62, 63, 64, 65, 66, 67, 68, 69, 70)
-
Specification